PortalPublikationenAllogeneic hematopoietic cell transplantation for multiple m...

Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party

Standard

Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. / Sobh, M; Michallet, M; Gahrton, G; Iacobelli, S; van Biezen, A; Schönland, S; Petersen, E; Schaap, N; Bonifazi, F; Volin, L; Meijer, E; Niederwieser, D; El Cheikh, J; Tabrizi, R; Fegeux, N; Finke, J; Bunjes, D; Cornelissen, J; Einsele, H; Bruno, B; Potter, M; Fanin, R; Mohty, M; Garderet, L; Kröger, N.

in: LEUKEMIA, Jahrgang 30, Nr. 10, 10.2016, S. 2047-2054.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Sobh, M, Michallet, M, Gahrton, G, Iacobelli, S, van Biezen, A, Schönland, S, Petersen, E, Schaap, N, Bonifazi, F, Volin, L, Meijer, E, Niederwieser, D, El Cheikh, J, Tabrizi, R, Fegeux, N, Finke, J, Bunjes, D, Cornelissen, J, Einsele, H, Bruno, B, Potter, M, Fanin, R, Mohty, M, Garderet, L & Kröger, N 2016, 'Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party', LEUKEMIA, Jg. 30, Nr. 10, S. 2047-2054. https://doi.org/10.1038/leu.2016.101

APA

Sobh, M., Michallet, M., Gahrton, G., Iacobelli, S., van Biezen, A., Schönland, S., Petersen, E., Schaap, N., Bonifazi, F., Volin, L., Meijer, E., Niederwieser, D., El Cheikh, J., Tabrizi, R., Fegeux, N., Finke, J., Bunjes, D., Cornelissen, J., Einsele, H., ... Kröger, N. (2016). Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. LEUKEMIA, 30(10), 2047-2054. https://doi.org/10.1038/leu.2016.101

Vancouver

Sobh M, Michallet M, Gahrton G, Iacobelli S, van Biezen A, Schönland S et al. Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. LEUKEMIA. 2016 Okt;30(10):2047-2054. https://doi.org/10.1038/leu.2016.101

Bibtex

@article{e4517e0dc651462b86659b77f32328f7,
title = "Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party",
abstract = "We describe the use and outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for multiple myeloma (MM) in Europe between January 1990 and December 2012. We identified 7333 patients, median age at allo-HSCT was 51 years (range: 18-78), of whom 4539 (62%) were males. We distinguished three groups: (1) allo-HSCT upfront (n=1924), (2) tandem auto-allo-HSCT (n=2004) and (3) allo-HSCT as a second line treatment and beyond (n=3405). Overall, there is a steady increase in numbers of allo-HSCT over the years. Upfront allo-HSCT use increased up to year 2000, followed by a decrease thereafter and represented 12% of allo-HSCTs performed in 2012. Tandem auto-allo-HSCT peaked around year 2004 and contributed to 19% of allo-HSCTs in 2012. Allo-HSCT as salvage after one or two or three autografts was steadily increasing over the last years and represented 69% of allo-HSCTs in 2012. Remarkable heterogeneity in using allo-HSCT was observed among the different European countries. The 5-year survival probabilities from time of allo-HSCT for the three groups after year 2004 were 42%, 54% and 32%, respectively. These results show that the use of allo-HSCT is increasing in Europe, especially as second line treatment and beyond. There is an unmet need for well-designed prospective studies investigating allo-HSCT as salvage therapy for MM.",
keywords = "Adolescent, Adult, Aged, Europe, Female, Hematopoietic Stem Cell Transplantation, Humans, Male, Middle Aged, Multiple Myeloma, Survival Rate, Transplantation, Homologous, Treatment Outcome, Young Adult, Journal Article",
author = "M Sobh and M Michallet and G Gahrton and S Iacobelli and {van Biezen}, A and S Sch{\"o}nland and E Petersen and N Schaap and F Bonifazi and L Volin and E Meijer and D Niederwieser and {El Cheikh}, J and R Tabrizi and N Fegeux and J Finke and D Bunjes and J Cornelissen and H Einsele and B Bruno and M Potter and R Fanin and M Mohty and L Garderet and N Kr{\"o}ger",
year = "2016",
month = oct,
doi = "10.1038/leu.2016.101",
language = "English",
volume = "30",
pages = "2047--2054",
journal = "LEUKEMIA",
issn = "0887-6924",
publisher = "NATURE PUBLISHING GROUP",
number = "10",

}

RIS

TY - JOUR

T1 - Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party

AU - Sobh, M

AU - Michallet, M

AU - Gahrton, G

AU - Iacobelli, S

AU - van Biezen, A

AU - Schönland, S

AU - Petersen, E

AU - Schaap, N

AU - Bonifazi, F

AU - Volin, L

AU - Meijer, E

AU - Niederwieser, D

AU - El Cheikh, J

AU - Tabrizi, R

AU - Fegeux, N

AU - Finke, J

AU - Bunjes, D

AU - Cornelissen, J

AU - Einsele, H

AU - Bruno, B

AU - Potter, M

AU - Fanin, R

AU - Mohty, M

AU - Garderet, L

AU - Kröger, N

PY - 2016/10

Y1 - 2016/10

N2 - We describe the use and outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for multiple myeloma (MM) in Europe between January 1990 and December 2012. We identified 7333 patients, median age at allo-HSCT was 51 years (range: 18-78), of whom 4539 (62%) were males. We distinguished three groups: (1) allo-HSCT upfront (n=1924), (2) tandem auto-allo-HSCT (n=2004) and (3) allo-HSCT as a second line treatment and beyond (n=3405). Overall, there is a steady increase in numbers of allo-HSCT over the years. Upfront allo-HSCT use increased up to year 2000, followed by a decrease thereafter and represented 12% of allo-HSCTs performed in 2012. Tandem auto-allo-HSCT peaked around year 2004 and contributed to 19% of allo-HSCTs in 2012. Allo-HSCT as salvage after one or two or three autografts was steadily increasing over the last years and represented 69% of allo-HSCTs in 2012. Remarkable heterogeneity in using allo-HSCT was observed among the different European countries. The 5-year survival probabilities from time of allo-HSCT for the three groups after year 2004 were 42%, 54% and 32%, respectively. These results show that the use of allo-HSCT is increasing in Europe, especially as second line treatment and beyond. There is an unmet need for well-designed prospective studies investigating allo-HSCT as salvage therapy for MM.

AB - We describe the use and outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for multiple myeloma (MM) in Europe between January 1990 and December 2012. We identified 7333 patients, median age at allo-HSCT was 51 years (range: 18-78), of whom 4539 (62%) were males. We distinguished three groups: (1) allo-HSCT upfront (n=1924), (2) tandem auto-allo-HSCT (n=2004) and (3) allo-HSCT as a second line treatment and beyond (n=3405). Overall, there is a steady increase in numbers of allo-HSCT over the years. Upfront allo-HSCT use increased up to year 2000, followed by a decrease thereafter and represented 12% of allo-HSCTs performed in 2012. Tandem auto-allo-HSCT peaked around year 2004 and contributed to 19% of allo-HSCTs in 2012. Allo-HSCT as salvage after one or two or three autografts was steadily increasing over the last years and represented 69% of allo-HSCTs in 2012. Remarkable heterogeneity in using allo-HSCT was observed among the different European countries. The 5-year survival probabilities from time of allo-HSCT for the three groups after year 2004 were 42%, 54% and 32%, respectively. These results show that the use of allo-HSCT is increasing in Europe, especially as second line treatment and beyond. There is an unmet need for well-designed prospective studies investigating allo-HSCT as salvage therapy for MM.

KW - Adolescent

KW - Adult

KW - Aged

KW - Europe

KW - Female

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Male

KW - Middle Aged

KW - Multiple Myeloma

KW - Survival Rate

KW - Transplantation, Homologous

KW - Treatment Outcome

KW - Young Adult

KW - Journal Article

U2 - 10.1038/leu.2016.101

DO - 10.1038/leu.2016.101

M3 - SCORING: Journal article

C2 - 27118410

VL - 30

SP - 2047

EP - 2054

JO - LEUKEMIA

JF - LEUKEMIA

SN - 0887-6924

IS - 10

ER -